Concentration of CCCP Should Be Optimized to Detect the Efflux System in Quinolone-Susceptible Escherichia coli

Journal of Microbiology

Volumn 39, Issue 1, 2001, Pages 62-66

  Cho, Hyengun ^a   Oh, Yoojung ^a   Park, Seohyung ^a   Lee, Yeonhee ^a  

^a Seoul Women University   (South Korea)

Author keywords

Antibiotic resistance; CCCP; E. Coli; Efflux; Quinolone

Indexed keywords

EID: 0010169954     PISSN: 12258873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Anton, D.N. 1995. Resistance to mecillinam produced by the co-operative action of mutations affecting lipopolysaccharide, spoT, and cya or crp genes of Salmonella typhimurium. Mol. Microbiol. 16, 587-595.
2. Bauemfeind, A. 1971. Mode of action of nalidixic acid. Antibiol. Chemother. 17, 122-136.
3. Chen, C.R., M. Malik, M. Snyder, and K. Drlica. 1996. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J. Mol. Biol. 258, 627-637.
4. Cohen, S.P, E.C. Hooper, J.S. Wolfson, L.M. McMurry, and S.B. Levy. 1998. Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob. Agents Chemother. 32, 1187-1191.
5. Fournier, B. and D.C. Hooper. 1998. Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity. Antimicrob. Agents Chemother. 42, 2109-2112.
6. Ghosh, A.S., J. Ahamed, K.K. Chauhan, and M. Kundu. 1998. Involvement of an efflux system in high-level fluoroquinolone resistance of Shigella dysenteriae. Biochem. Biophys. Res. Comm. 242, 54-56.
7. Heisig, P. 1996. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40, 879-885.
8. Hooper, D.C. 1995. Quinolone mode of action. Drugs 49 (suppl.2), 10-15.
9. Jalal, S. and B. Wretlind. 1998. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb. Drug Resist. 4, 257-261.
10. Jorgensen, J.H., L.M. Weigel, M.J. Ferraro, J.M. Swenson, and F.C. Tenover. 1999. Activities of newer fluoroquinolones against Streptococcus pnemoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob. Agents Chemother. 43, 329-334.
11. Kaneko, M., A. Yamaguchi, and T. Sawai. 1985. Energetics of tetracycline efflux system encoded by Tn10 in Escherichia coli. FEBS Lett. 193, 194-198.
12. Kim, K., S. Lee, and Y. Lee. 1996. Norfloxacin resistance mechanism of E. coli 11 and E. coli 101-clinical isolates of Escherichia coli in Korea. Arch. Pharm. Res. 19, 353-358.
13. Kohler, T., M. Michea-Hamzehpour, P. Pleisiat, A.L. Kahr, and J.C. Pechere. 1997. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41, 2540-2543.
14. Lee, S. and Y. Lee. 1998. Ofloxacin resistance mechanism in PA 150 and PASOO-clinical isolates of Pseudomonas aeruginosa in Korea. Arch. Pharm. Res. 21, 671-676.
15. Leying, H.J., K.H. Bucher, W. Cullmann, and R.L. Then. 1992. Lipopolysaccharide alterations responsible for combined quinolone and beta-lactam resistance in Pseudomonas aeruginosa. Chemotherapy 38, 82-91.
16. Lolkema, J.S., B. Poolman, and W.N. Konings. 1998. Bacterial solute uptake and efflux systems. Curr. Opin. Microbiol. 1, 248-253.
17. Mallea, M., J. Chevalier, C. Bornet, A. Eyraud, A. Davin-Regli, C. Bollet, and J.M. Pages. 1998. Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. Microbiol. 144, 3003-3009.
18. Maseda, H., H. Yoneyama, and T. Nakae. Assignment of the substrate-selective subunits of the MexEF-OprN multidrug efflux pump of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44, 658-664.
19. Munoz-Bellido J.L., A. Manzanares, M. Andrea, G. Zufiaurre, G. Ortiz, S. Hernendez, and G. Rodriguez. 1999. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob. Agents Chemother. 43, 354-356.
20. Nagata, S. 1995. Lethal effect of carbonyl cyanide m-chlo-rophenylhydrazone on Escherichia coli and a halotolerant Brevibacterium species. Microbios 81, 73-83.
21. Nikaido, H. 1994. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264, 382-388.
22. Nikaido, H. 1998. Multidrug antibiotic resistance and efflux. Curr. Opin. Microbiol. 1, 516-523.
23. Ng, E.Y., M. Trucksis, and D.C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40, 1881-1888.
24. Oethinger, M., W.V. Kem, J.D. Goldman, and S.B. Levy. Association of organic solvent tolerance and fluoroquinolone resistance in clinical isolates of Escherichia coli. J. Antimicrob. Chemother. 41, 111-114.
25. Pan, X.S. and L.M. Fisher. 1998. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42, 2810-2816.
26. Park, S., S. Lee, and Y. Lee. 1996. Norfloxacin Resistance mechanism of Escherichia coli 59-a clinical isolate in Korea. Mol. Cells 6, 469-472.
27. Paulsen, I.T., M.H. Brown, and R.A. Skurray. 1996. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60, 575-608.
28. Yamano, Y., T. Nishikawa, and Y. Komatsu. 1990. Outer membrane proteins responsible for the penetration of beta-lactams and quinolones in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 26, 175-184.